runaway demand cgm drive signific
upsid pt
put beat cgm demand surg front us
medicar ou newest sensor littl impact given late
launch top-lin guidanc go higher prior
gm guidanc lower manufactur varianc
product ramp show two compel trend cgm adopt
acceler lose share combo keep us firmli
growth driver acceler cgm adopt demand pull big
stori believ set drive share new all-tim high
outsiz top-lin print growth acceler actual
manag clear perform predominantli driven surg
demand/uptak current sensor given new sensor factori calibr
day wear launch week left sharp rise growth
come even abbott continu forg ahead aggress market
offer libr gaurdian connect effort part competitor
appear drive sizabl amount new patient cgm broadli
opportunist beneficiari although littl impact point toward
promot activ ahead fuller-scal launch suggest least
beat could demand pull relat
gm setback manufactur constraint price one off-set
reduct gm guidanc midpoint revis prior due
manufactur constraint mix price manufactur setback due shift
product line new hire ineffici struggl meet demand
shift toward medicar ou also pressur margin carri lower revenue-per-
patient broader comment price suggest contempl addit pressur
pursu addit channel distribut though price concess face
competit seem materi differenti better perform
continu insul product competit
rais pt still top idea estim go
prior reflect increas top-lin guidanc off-set lower gm
could prove conserv given launch cgm adopt still
hover around neglig outlook market remain
signific believ still best posit
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
preval type diabet continu
increas larg driven demograph
increas focu lower cost treat diabet
improv technolog use novel devic
like cgm grow
face increas competit sole
focu cgm continu product differenti
compani remain signific player market
estim global net patient addit
despit competit abbott
tailwind medicar reimburs felt throughout
revenu growth driven new patient add
price target deriv use sale
growth exceed driven increas patient add
competit less impact fear
clinic data drive increas usag type patient
price target deriv use multipl
updat google/verili type product
approv launch artifici pancrea devic
approv launch tandem artifici pancrea devic
revenu growth slow fewer patient
addit well defect user base
product delay due regulatori pathway
libr take signific share us
price target deriv use multipl lower
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
